Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America

Cambrex completes US$38 million capacity expansion in High Point, North Carolina

Lonza further extends collaboration with major biopharmaceutical partner for manufacturing antibody-drug conjugates

The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation

Marksans Pharma gets USFDA approval for Esomeprazole Magnesium delayed-release capsules

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals

Mandaviya reviews preparedness to prevent rising dengue cases

Minister was briefed on the nationwide dengue situation

27,353 hospitals empanelled under PM-JAY

30 beneficiaries avail of services per minute

Arogya Manthan 2023 to mark 5 years of Ayushman Bharat PM-JAY

National Health Authority (NHA) to host the two-day Arogya Manthan event in New Delhi

India becomes role model in crisis management and preventive healthcare: Dr. Jitendra Singh

Dr. Jitendra Singh inaugurates 300 LPM capacity Oxygen Plant, Day Care Chemotherapy Unit affiliated to Tata Memorial Hospital & Maternal ICU at GMC Kathua

Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Clindamycin Phosphate Gel is used to treat acne

CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData

CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology